Advocacy intelligence hub — real-time data for patient organizations
Treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older
University of Southern California — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Filsuvez
(BIRCH TRITERPENES)Orphan drugChiesi USA, Inc.
12.1 Mechanism of Action The mechanism of action of FILSUVEZ in the treatment of wounds associated with epidermolysis bullosa is unknown.
Alexandra DJ Mancini, MSc, OTR/L
InMed Pharmaceuticals Inc.
📍 GREENACRES, FL
Benjamin E Low
The Jackson Laboratory
📍 SAN FRANCISCO, CA
Cristina Magnoni
Struttura Complessa di Dermatologia Azienda Ospedaliero Universitaria Policlinico di Modena
Oliver Patrick March
University Hospital of the Paracelsus Medical University Salzburg
Igor Petković
University Hospital of the Paracelsus Medical University Salzburg
Robert Y Wilpan
The Jackson Laboratory